RC
ANTX icon

Rangeley Capital’s AN2 Therapeutics ANTX Stock Holding History

Rangeley Capital’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-65,000
Closed -$74.1K – 139
2025
Q4 		$74.1K Hold
65,000
– – 0.06% 110
2025
Q3 		$82.5K Hold
65,000
– – 0.07% 113
2025
Q2 		$68.9K Buy
65,000
+15,000
+30% +$17.9K 0.08% 60
2025
Q1 		$68K Buy
+50,000
New +$62.9K 0.07% 73

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Rangeley Capital's ANTX Position: Q1 2026 in Review

Rangeley Capital sold out of AN2 Therapeutics (ANTX) in Q1 2026, closing a stake of 65,000 shares — an estimated $74.1K sold.

Rangeley Capital first reported a position in ANTX in Q1 2025 and held it in 4 quarters. The position peaked at $82.5K in Q3 2025. 52 funds tracked by Wall St. Rank hold ANTX as of Q1 2026.

  • Rangeley Capital reported no remaining AN2 Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rangeley Capital sold 65,000 AN2 Therapeutics shares in Q1 2026, an estimated $74.1K.
  • Rangeley Capital first reported a position in AN2 Therapeutics in Q1 2025 and held it in 4 quarters.
  • Rangeley Capital's AN2 Therapeutics position peaked at $82.5K in Q3 2025.
  • 52 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q1 2026.

Based on Rangeley Capital's 13F filing for Q1 2026, filed 15 May 2026.